Nathalie Vanlaer

Ms. Nathalie Vanlaer

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2023 in Psychologica Belgica
Verified
Journal Article
Open access
PDF file
ARAurore Roland
Aurore Roland
CCClara Colomb
Clara Colomb
SNStéphane Noël
Stéphane Noël
Arcady A. PutilovArcady A. Putilov
Arcady A. Putilov
Halszka OginskaHalszka Oginska
Halszka Oginska
OMOlivier Mairesse
Olivier Mairesse
Belgium has one of the highest numbers of COVID-19 cases per 1 million inhabitants. The pandemic has led to significant societal changes with repercussions on sleep and on mental health. We aimed to investigate the effect of the first and the second wave of COVID-19 on the sleep of the Belgian populationWe launched two online questionnaires, one during the first lockdown (7240 respondents) and one during the second (3240 respondents), to test differences in self-reported clinical insomnia (as measured by the Insomnia Severity Index) and sleep habits during the two lockdowns in comparison with the pre-COVID period. The number of persons with clinical insomnia rose during the first lockdown (19.22%) and further during the second (28.91%) in comparison with pre-lockdown (7.04-7.66%). Bed and rise times were delayed and there was an increased time in bed and sleep onset latency. There was further a decrease in total sleep time and in sleep efficiency during both confinements. The prevalence of clinical insomnia quadrupled during the second wave in comparison with the pre-lockdown situation. Sleep habits were most altered in the younger population, indicating a greater risk for this group to develop a sleep-wake rhythm disorder.

24 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
NVNathalie Vanlaer
Nathalie Vanlaer
IDiris dirven
iris dirven
BNBart Neyns
Bart Neyns
ARAnne Rogiers
Anne Rogiers
Background: There is a need for a better understanding of survivorship-related issues in advanced cancer survivors treated with immune checkpoint blockade (ICB). The purpose of this study was to identify survivorship-related issues, with a focus on psychological distress, cognitive complaints, physical sequelae, impact on family dynamics, and care needs in unresectable, advanced cancer survivors treated with ICB. Methods: Semi-structured interviews and patient-reported outcome measures (PROMs) were conducted in survivors followed up at the University Hospital Brussels. We performed content analysis on the semi-structured interviews and analyzed the PROMs descriptively. Results: 70 cancer survivors (71.4%) consented to participate between July 2022 and November 2023. Clinical fear of cancer recurrence (FCR) was present in 54.3% of the cancer survivors, and 18.6% had elevated cognitive complaints. We identified triggers related to clinically important psychological distress, such as immune-related adverse events, the progression/recurrence of disease, difficulties in adjusting to life after treatment, and co-existing life stressors, alongside persistent physical issues and unmet psychological and nutritional care needs. Conclusion: Our results indicate the existence of persistent psychological, physical, and cognitive issues, and support the need for routine screening for FCR. The identified triggers related to severe psychological distress can aid clinicians in timely referring the patient, thereby enhancing survivorship care.

19 March 2024 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
WGWietse Geens
Wietse Geens
NVNathalie Vanlaer
Nathalie Vanlaer
LNLynn Nijland
Lynn Nijland
SLSven Van Laere
Sven Van Laere
JSJulia Katharina Schwarze
Julia Katharina Schwarze
JDJohnny Duerinck
Johnny Duerinck


9 April 2026 in ESMO Open
Verified
Journal Article
Open access
IDiris dirven
iris dirven
BCBertels Cleo
Bertels Cleo
YMY. Moreels
Y. Moreels
JKJ.I. Kessels
J.I. Kessels
NVNathalie Vanlaer
Nathalie Vanlaer
BNBart Neyns
Bart Neyns
Most patients with advanced melanoma progress despite standard-of-care treatments. Regorafenib (REGO), an oral multikinase inhibitor with RAF-dimer activity, demonstrated clinical activity in melanoma in retrospective case series and preclinical efficacy in overcoming resistance to BRAF/MEK inhibitors (BRAF/MEKi). This study prospectively evaluated REGO in heavily pretreated advanced melanoma patients. This single-center, phase II clinical trial (RegoMel, NCT05370807) assessed the objective response rate (ORR) upon continuous REGO dosing (40-120 mg daily) in 16 patients with advanced pretreated melanoma, regardless of the melanoma driver mutation. In BRAFV600-mutant patients, BRAF/MEKi addition was permitted upon progression on REGO monotherapy. Based on early efficacy signs, a KIT-mutant expansion cohort was also recruited and analyzed. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. There was one complete (BRAFV600-mutant) and five partial responses [KIT- (n = 3), BRAFV600-mutant (n = 2); ORR 37.5%; disease control rate (DCR) 56%]. Median duration of response was 37.4 weeks with median PFS (mPFS) and mOS of 12.1 weeks and 75.8 weeks, respectively. In the KIT-mutant expansion cohort (N = 9), ORR and DCR were 78% and 100%, respectively, and mPFS 43.4 weeks; mOS was not reached. Six BRAFV600-mutant patients received REGO + BRAF/MEKi at first progression (ORR 33%, DCR 83%, mPFS 20.4 weeks, mOS 62.1 weeks). Grade 3 treatment-related adverse events (TRAEs) occurred in 59% of patients on REGO monotherapy and 50% on REGO + BRAF/MEKi. The most common TRAEs were hand-foot-skin reaction, hypertension, and diarrhea. All TRAEs were reversible. This phase II clinical trial met its primary endpoint, demonstrating clinically meaningful antitumor activity and manageable toxicity with continuous daily REGO in advanced pretreated melanoma. The unprecedented high response rates in KIT-mutant melanoma and encouraging activity in BRAFV600-mutant patients receiving REGO + BRAF/MEKi support further investigation of REGO-based regimens in these subpopulations of melanoma patients.

20 October 2023 in Annals of Oncology
Verified
Journal Article
Closed access
NVNathalie Vanlaer
Nathalie Vanlaer
IDI. Dirven
I. Dirven
MVM. Vounckx
M. Vounckx
JTJ. Tijtgat
J. Tijtgat
MVM. Verhaert
M. Verhaert
BNB. Neyns
B. Neyns